原发性硬化性胆管炎肝移植后环孢素与他克莫司比较:倾向性评分匹配的意向性治疗分析
基于欧洲与美国登记库,纳入2000至2020年接受首次肝移植的成人原发性硬化性胆管炎患者,将初始环孢素治疗者按1:3倾向性评分匹配至初始他克莫司治疗者。匹配样本含399例环孢素治疗者和1197例他克莫司治疗者,中位随访7.4年。他克莫司组患者和移植物生存率均优于环孢素组,10年患者生存率分别为72.8%和65.2%(p<0.001),10年移植物生存率分别为62.4%和53.8%(p<0.001)。作者认为他克莫司应作为原发性硬化性胆管炎肝移植后标准钙调神经磷酸酶抑制剂。
要点
- 他克莫司组10年患者生存率72.8%,环孢素组65.2%(p<0.001)。
- 他克莫司组10年移植物生存率62.4%,环孢素组53.8%(p<0.001)。
- 多变量Cox回归中他克莫司与移植物丢失或死亡风险降低相关(HR 0.72,p<0.001)。
核心结论
- 他克莫司与环孢素相比,患者和移植物生存率更优,应作为原发性硬化性胆管炎患者肝移植后标准钙调神经磷酸酶抑制剂。
研究设计与样本
- 基于欧洲肝移植登记库(ELTR)和移植受者科学登记库(SRTR)的倾向性评分匹配意向性治疗分析。
- 纳入2000至2020年接受首次肝移植的成人原发性硬化性胆管炎患者,初始环孢素治疗者按1:3倾向性评分匹配至初始他克莫司治疗者。
- 匹配样本含399例环孢素治疗者和1197例他克莫司治疗者。
主要发现
- 中位随访7.4年(IQR 2.3-12.8,12579.2人年),共480例死亡和231例再移植。
- 他克莫司组10年患者生存率72.8%,环孢素组65.2%(p<0.001)。
- 他克莫司组10年移植物生存率62.4%,环孢素组53.8%(p<0.001)。
- 按年龄、性别、登记库(ELTR vs. SRTR)、肝移植时间段、MELD评分和糖尿病状态分层的亚组结果一致。
- 两组急性排斥率相似。
关键数值与推荐
- 多变量Cox回归分析中,他克莫司与移植物丢失或死亡风险降低相关(HR 0.72,p<0.001)。
- 多变量Cox回归分析中,吗替麦考酚酯使用与移植物丢失或死亡风险降低相关(HR 0.82,p=0.03)。
- 多变量Cox回归分析中,激素使用未达统计学显著。
临床怎么用
- 作者结论认为他克莫司应作为原发性硬化性胆管炎患者肝移植后标准钙调神经磷酸酶抑制剂。
- 作者研究支持在原发性硬化性胆管炎患者肝移植后初始免疫抑制方案中使用他克莫司而非环孢素。
局限性
- 原文指出回顾性登记库设计是局限性。
- 原文指出由于长期随访的随机试验不太可能进行,多大陆长期登记库数据对指导临床实践至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy regarding the optimal calcineurin inhibitor type after liver transplant(ation) (LT) for primary sclerosing cholangitis (PSC). We compared tacrolimus with cyclosporine in a propensity score-matched intention-to-treat analysis based on registries representing nearly all LTs in Europe and the US. METHODS: From the European Liver Transplant Registry (ELTR) and Scientific Registry of Transplant Recipients (SRTR), we included adult patients with PSC undergoing a primary LT between 2000-2020. Patients initially treated with cyclosporine were propensity score-matched 1:3 with those initially treated with tacrolimus. The primary outcomes were patient and graft survival rates. RESULTS: The propensity score-matched sample comprised 399 cyclosporine-treated and 1,197 tacrolimus-treated patients with PSC. During a median follow-up of 7.4 years (IQR 2.3-12.8, 12,579.2 person-years), there were 480 deaths and 231 re-LTs. The initial tacrolimus treatment was superior to cyclosporine in terms of patient and graft survival, with 10-year patient survival estimates of 72.8% for tacrolimus and 65.2% for cyclosporine (p <0.001) and 10-year graft survival estimates of 62.4% and 53.8% (p <0.001), respectively. These findings were consistent in the subgroups according to age, sex, registry (ELTR vs. SRTR), time period of LT, MELD score, and diabetes status. The acute rejection rates were similar between groups. In the multivariable Cox regression analysis, tacrolimus (hazard ratio 0.72, p <0.001) and mycophenolate use (hazard ratio 0.82, p = 0.03) were associated with a reduced risk of graft loss or death, whereas steroid use was not significant. CONCLUSIONS: Tacrolimus is associated with better patient and graft survival rates than cyclosporine and should be the standard calcineurin inhibitor used after LT for patients with PSC. IMPACT AND IMPLICATIONS: The optimal calcineurin inhibitor to use after liver transplantation in patients with primary sclerosing cholangitis has yet to be firmly established. Since randomized trials with long follow-up are unlikely to be performed, multicontinental long-term registry data are essential in informing clinical practices. Our study supports the practice of using tacrolimus instead of cyclosporine in the initial immunosuppressive regimen after liver transplantation for patients with primary sclerosing cholangitis. The retrospective registry-based design is a limitation.
引用
- Åberg F, Sallinen V, Tuominen S, et al. Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis. J Hepatol. 2023. PMID: 37722533. doi:10.1016/j.jhep.2023.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。